Startup CytoScale Diagnostics to Commercialize UCLA's Single-Cell Protein Biomarker Platform | GenomeWeb

This story originally ran on Aug. 5.

By Adam Bonislawski

CytoScale Diagnostics, a biotech startup formed in April by recent graduates of the University of California, Los Angeles, MBA program, has licensed a chip-based microfluidic image-cytometry platform and accompanying brain tumor biomarker assay from UCLA researchers that it plans to commercialize by the end of 2013.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.